Custom Antibody Market is expected to growth at CAGR 9.80% during the forecast period 2022-2030
$352 Million
9.80%
North America
2022-2030
Custom Antibody Market Overview
The custom antibody market is projected to reach USD 352 Million by 2030 at 9.80% CAGR during the forecast period 2022-2030. All types of research studies are widely preferred to the custom antibody because it provides high selectivity and specificity. Also, it is widely used in research studies because it is considered easy to produce compared to any other antibodies.
The demand for Custom Antibody Market is expanding due to the rising association with the academic centers and industry and rising research activity in the life sciences industry. The custom antibody has benefits for the research studies as it accomplishes well in quantitative or qualitative immunodetection. The present market shows serious concern about the quality of catalogue antibodies. Therefore, the end-users are widely preferring to the use of custom-made antibodies. Moreover, the rising research and development activities amongst the major key players and new product launches are predicted to bring lucrative growth opportunities for the Custom Antibody Market. Additionally, the rising demand for personalized medicine in protein therapeutics is projected to bring significant growth opportunities to the global market during the forecast period. However, the presence of alternative antibodies might bring challenges to the worldwide market during the assessment period.
Segmentation: The Custom Antibody Market has been segmented on the basis of service, source, type, research area and end users.
On the basis of service, the market has been classified as antibody development, antibody production & purification, antibody fragmentation & labeling. The antibody development is segmented in to antibody characterization, antigen preparation, immunization & hybridoma production.
On the basis of source, the market has been classified as mice, rabbits, human beings and others.
On the basis of type, the market has been classified as monoclonal antibodies, polyclonal antibodies, recombinant antibodies, others.
On the basis of research area, the market has been classified as oncology, infectious diseases, immunology, neurobiology, stem cells, cardiovascular diseases, other research areas
On the basis of end users, the market has been classified as pharmaceutical & biotechnology companies, hospitals and clinics, academic & research institutes, contract research organizations.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European custom antibody market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The custom antibody market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The custom antibody market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Custom Antibody Market Share, by Region, 2017 (%)
Source: MRFR Analysis
In the custom antibody market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into disease treatment. The largest market share is credited to the increasing focus of researchers on high-quality antibodies for reproducibility, which can be hampered by using commercially available antibodies.The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to Capra Science, a European company specialized in custom antibody production, llama-derived nanobodies might find therapeutic application in Parkinson’s disease.
Whereas the Asia-Pacific region is projected to be the fastest growing segment experience in the near future due to the growing therapeutic industry in India and China, also the increasing funds in life science research by the government organizations of these countries are aspects driving the growth of the Asia-Pacific market. Similarly, the increasing research in genomics and proteomics, growing investments by pharmaceutical companies, rising awareness about personalized therapeutics, and growing research activities in the field of mAb-based therapeutics are boosting the growth of this custom antibody market in Asia-Pacific region.
The market in the Middle East & Africa is expected to account for the smallest share of the global custom antibody market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.
Key Players: Some of the key players in the global custom antibody market are Thermo Fisher Scientific Inc., Genscript, Abcam PLC, Merck Group, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Agilent Technologies, Inc., Biolegend, Inc., Rockland Immunochemicals Inc., Promab Biotechnologies, Inc., Proteogenix, Innovagen Ab.
Custom Antibody Market, by Service:
Custom Antibody Market, by Source:
Custom Antibody Market, by Type:
Custom Antibody Market, by Research Area:
Custom Antibody Market, by End-Users:
Custom Antibody Market, by Region:
Company Profiles:
Recent Development
In 2021, the prominent players SunRock Biopharma and GenScript announced their collaboration. This collaboration has aimed to develop therapeutic antibody candidates. Here, SunRock Biopharma is receiving a better solution from GenScript for cell line development, antibody discovery, drug product manufacturing services, and process development for GMP drug substances. In the same year, the market leaders Abingdon Health (UK) and Abcam plc signed a co-marketing agreement and started doing collaboration work. This collaboration has aimed to enhance the customer base of Abcam.Intended Audience:
Â
Report Attribute/Metric | Details |
---|---|
Market Size | 352 Million |
CAGR | 9.80% |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Service, Source, Type, Research area and End users |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Thermo Fisher Scientific Inc., Genscript, Abcam PLC, Merck Group, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Agilent Technologies, Inc., Biolegend, Inc., Rockland Immunochemicals Inc., Promab Biotechnologies, Inc., Proteogenix, Innovagen Ab |
Key Market Opportunities | New product launches and R&D Amongst major key Players |
Key Market Drivers |
|